马拉维成人脑膜炎评分预测资源匮乏高HIV流行区细菌性脑膜炎结局
本研究基于马拉维成人急性细菌性脑膜炎(ABM)患者发现数据库(n=523,65%脑脊液培养阳性)建立并内部验证马拉维成人脑膜炎评分(MAMS)列线图,6周随访死亡率为54%。MAMS区分度C指数0.76(95%CI .71-.80),校准良好;在预测风险25%-50%组中辅助甘油显示有害效应(安慰剂组病死率21% vs 甘油组52%,P<.001),地塞米松未见此效应。
要点
- MAMS列线图基于脑脊液培养阳性、脑脊液白细胞计数、血红蛋白、格拉斯哥昏迷评分和脉率5个预测因子。
- MAMS区分度C指数0.76(95%CI .71-.80),校准良好(Hosmer-Lemeshow C统计量=5.48,df=8,P=.705)。
- 预测风险25%-50%组辅助甘油有害(病死率21% vs 52%,P<.001),地塞米松未见此效应。
核心结论
- MAMS可用于资源匮乏地区成人ABM的预后预测和临床试验风险分层。
- MAMS能否应用于非HIV流行国家尚需进一步评估。
研究设计与样本
- 基于马拉维成人ABM发现数据库(n=523,65%脑脊液培养阳性)建立列线图,采用bootstrap法内部验证。
- 利用马拉维临床试验数据以MAMS评分进一步解释辅助地塞米松和甘油的效果。
主要发现
- 6周随访ABM死亡率为54%。
- 15个测试变量中5个与不良结局强相关:脑脊液培养阳性、脑脊液白细胞计数、血红蛋白、格拉斯哥昏迷评分和脉率。
- MAMS列线图C指数(曲线下面积)为0.76(95%CI .71-.80),校准良好(Hosmer-Lemeshow C统计量=5.48,df=8,P=.705)。
- 预测风险25%-50%组中辅助甘油有害:安慰剂组病死率21%,甘油组52%(P<.001);地塞米松未见此效应。
关键数值与推荐
- MAMS列线图采用5个预测因子:脑脊液培养阳性、脑脊液白细胞计数、血红蛋白、格拉斯哥昏迷评分和脉率。
- MAMS区分度C指数0.76(95%CI .71-.80),校准Hosmer-Lemeshow C统计量=5.48,df=8,P=.705。
- 预测风险25%-50%组辅助甘油病死率52% vs 安慰剂21%(P<.001)。
临床怎么用
- 可用MAMS对资源匮乏地区成人ABM患者进行死亡风险分层。
- 在预测风险25%-50%组应避免辅助甘油。
- MAMS有助于优化ABM临床试验设计和标准化临床算法的解读。
局限性
- MAMS仅进行内部验证,未做外部验证。
- 研究人群为马拉维高HIV流行资源匮乏地区成人,向非HIV流行国家推广需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute bacterial meningitis (ABM) in adults residing in resource-poor countries is associated with mortality rates >50%. To improve outcome, interventional trials and standardized clinical algorithms are urgently required. To optimize these processes, we developed and validated an outcome prediction tool to identify ABM patients at greatest risk of death. METHODS: We derived a nomogram using mortality predictors derived from a logistic regression model of a discovery database of adult Malawian patients with ABM (n = 523 [65%] cerebrospinal fluid [CSF] culture positive). We validated the nomogram internally using a bootstrap procedure and subsequently used the nomogram scores to further interpret the effects of adjunctive dexamethasone and glycerol using clinical trial data from Malawi. RESULTS: ABM mortality at 6-week follow-up was 54%. Five of 15 variables tested were strongly associated with poor outcome (CSF culture positivity, CSF white blood cell count, hemoglobin, Glasgow Coma Scale, and pulse rate), and were used in the derivation of the Malawi Adult Meningitis Score (MAMS) nomogram. The C-index (area under the curve) was 0.76 (95% confidence interval, .71-.80) and calibration was good (Hosmer-Lemeshow C-statistic = 5.48, df = 8, P = .705). Harmful effects of adjunctive glycerol were observed in groups with relatively low predicted risk of poor outcome (25%-50% risk): Case Fatality Rate of 21% in the placebo group and 52% in the glycerol group (P < .001). This effect was not seen with adjunctive dexamethasone. CONCLUSIONS: MAMS provides a novel tool for predicting prognosis and improving interpretation of ABM clinical trials by risk stratification in resource-poor settings. Whether MAMS can be applied to non-HIV-endemic countries requires further evaluation.
引用
- Wall EC, Mukaka M, Scarborough M, et al. Prediction of Outcome From Adult Bacterial Meningitis in a High-HIV-Seroprevalence, Resource-Poor Setting Using the Malawi Adult Meningitis Score (MAMS). Clin Infect Dis. 2017. PMID: 27927860. doi:10.1093/cid/ciw779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。